Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

RNN $0.73 0.0680 +10.27%
IMNP $3.79 0.2900 +8.29%
MRTX $18.07 1.3200 +7.88%
CBMG $18.40 1.2850 +7.51%
MGNX $20.15 1.3000 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TGTX $8.26 -1.3350 -13.92%
VRML $2.37 -0.1300 -5.20%
GERN $2.59 -0.1300 -4.78%
CNDO $1.64 -0.0600 -3.53%
CTIC $2.66 -0.0800 -2.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Promising Phase II Results for Agenus' Brain Cancer Vaccine

(GEN) July 1, 2014 - The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.
read article 



HIV-Infected People with Early-Stage Cancers Are Up to Four Times More Likely to Go Untreated for Cancer, Penn Study Finds

(Penn Medicine) June 30, 2014 - HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine’s Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology.
read press release 



Most Women Can Get Fewer Pelvic Exams, Group Says

(ABC News/Associated Press) June 30, 2014 - No more dreaded pelvic exam? New guidelines say most healthy women can skip the yearly ritual.
read article 



Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia

(MarketWatch) July 1, 2014 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE®) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow.
read article 



Guideline Calls Routine Pelvic Exams Unnecessary

(New York Times) June 30, 2014 - Doctors should stop performing routine pelvic exams, a key component of regular physicals for women, an influential medical group said Monday.
read article 



If You’re HIV-Positive, You’re Less Likely to Get Cancer Treatment

(Newsweek) June 30, 2014 - Scientists have long recognized that cancer patients with HIV infections have lower survival rates than cancer patients without the virus.
read article 



Agenus Brain Cancer Vaccine Nearly Doubles Survival Rate in Study

(Reuters) July 1, 2014 - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.
read article 



First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax’s Entinostat

(PRWeb) June 30, 2014 - The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast cancer.
read press release 



Concerns Rise About Delays In Getting Generic Drugs To Market

(Kaiser Health News) June 30, 2014 - PBS NewsHour explores concerns that settlements on patents for drugs sometimes delay the generic version getting to consumers.
read article 



Medical Boards Draft Plan To Ease Path To Out-of-State And Online Treatment

(New York Times) June 29, 2014 - Officials representing state medical boards across the country have drafted a model law that would make it much easier for doctors licensed in one state to treat patients in other states, whether in person, by videoconference or online.
read article 



Allergan's Ozurdex Gets FDA Nod

(Wall Street Journal) June 30, 2014 - Allergan Inc. said Monday that the U.S. Food and Drug Administration had approved its Ozurdex eye treatment, while reporting positive midstage results for other drugs in its pipeline.
read article (paid subscription required) 



MannKind Caps Decade of Effort With U.S. Approval of Inhaled Insulin

(Bloomberg) June 30, 2014 - MannKind Corp. won U.S. approval to sell its inhaled insulin, culminating an almost decade-long effort, with a warning that the product shouldn’t be used by those with asthma or a serious lung disease.
read article 



Supreme Court Sides with Employers Over Birth Control Mandate

(Washington Post) June 30, 2014 - The Supreme Court struck a key part of President Obama’s health-care law Monday, ruling that some companies may refuse to offer insurance coverage of specific birth control methods if they conflict with the owner’s religious beliefs.
read article (free registration required) 



Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation (MMRF), Becomes Executive Chairman of the MMRF Board of Directors; Walter Capone Becomes President and CEO

(MMRF) June 30, 2014 - The Multiple Myeloma Research Foundation (MMRF) today announced that Kathy Giusti, Founder and CEO of the MMRF and the Multiple Myeloma Research Consortium (MMRC), will become the Executive Chairman of the MMRF Board of Directors.
read press release 



Holy Name Medical Center Welcomes Sharyn N. Lewin, MD, FACS and Phyllis Tarallo, DNP, DCC

(Holy Name Medical Center [Teaneck, NJ]) June 30, 2014 - Holy Name Medical Center (HNMC) welcomes gynecologic oncologist, hereditary cancer risk and women's health specialists Sharyn N. Lewin, MD, FACS, and Phyllis Tarallo, DNP, DCC, both of whom will be members of the Holy Name Physician Network.
read press release 



The Association of Community Cancer Centers Announces 2014 Innovator Award Recipients

(ACCC) June 23, 2014 - The Association of Community Cancer Centers (ACCC) is pleased to announce that six cancer programs have been selected as 2014 Innovator Award recipients for their pioneering solutions in the effective delivery of cancer care.
read press release 



Reed Introduces Bill That Would Reform CMS’s “Packaged Payment” Policy

(The Ripon Advance [Washington, DC]) June 27, 2014 - Bipartisan legislation recently introduced by Rep. Tom Reed (R-N.Y.) would ensure that Medicare recipients suffering from cancer and other illnesses are able to use the most recent, advanced treatments.
read article 



$16.7 Million Award in Cancer Lawsuit

(Boston Globe) June 30, 2014 - A jury has awarded $16.7 million to the daughter of a Boston woman who died of lung cancer after a radiologist missed evidence of the cancer in a chest X-ray.
read article (free registration required) 



US Oncology Research Launches Innovative Clinical Trial Focused on Preventing Chemotherapy-Induced Hair Loss

(Yahoo! Finance) June 30, 2014 - US Oncology Research—one of the largest community-based cancer research programs in the nation—and Baylor College of Medicine have recently launched a clinical trial to study a scalp cooling system designed to prevent chemotherapy-induced hair loss (alopecia).
read article 



Better, Faster, Cheaper

(Forbes/Techonomy.com) June 26, 2014 - To beat cancer we need more targeted drugs, made faster, made cheaper. And that means we need to fix the way cancer drugs are made.
read article 



Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute

(ABC12.com [Flint, MI]) June 30, 2014 - Trovagene, Inc., the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.
read article 



RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG

(RedHill Biopharma) June 30, 2014 - RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex AG.
read corporate press release 



Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma

(MarketWatch) June 30, 2014 - Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma.
read article 



Concern at Lack of Teenage Patients in Cancer Trials

(Cancer Research UK/NCRI) June 30, 2014 - Age limits on clinical trials need to be more flexible to allow more teenage cancer patients the chance to access new treatments, according to a report from the National Cancer Research Institute (NCRI), published in the Lancet Oncology today (Monday).
read press release 



Nearly Three-Fourth of Skin Cancers OK for Mohs Surgery

(Monthly Prescribing Reference/HealthDay News) June 27, 2014 — Application of recently published appropriate-use criteria suggests Mohs micrographic surgery (MMS) can be used in nearly three-quarters of skin cancers, according to a study published in the July issue of the Journal of the American Academy of Dermatology.
read article